

REMARKS

Applicants respectfully request reconsideration of the advisory action mailed December 10, 2003 in the above-identified application. As per the Examiner's suggestion, the term "antigen binding fragment" is now "F(ab')₂ fragment".

As noted during the telephone call to Examiner Ewoldt on December 12, 2003, Applicants believe that the amended claims specifically recite the subject matter which the Examiner indicated in the September 11, 2003 Office Action was enabling. Accordingly, the enablement rejection has been obviated and should be withdrawn.

The remaining rejection under 35 U.S.C. §112, first paragraph was obviated by the cancellation of claim 2.


Reconsideration of this application is requested.

In view of the above and foregoing, it is respectfully submitted that the claims now on file are believed to be in condition for allowance, and prompt and favorable action is earnestly solicited. Should there be any question concerning this response or the application in general, the Examiner is respectfully urged to telephone the undersigned so that prosecution of this application may be expedited.

Authorization is hereby given to the Commissioner to charge any defiant fees or to credit an overpayment to account number 50-0850.

Date: 12/17/03

Respectfully submitted,



David S. Resnick (Reg. No. 34,235)
NIXON PEABODY LLP
101 Federal Street
Boston, MA 02110
(617) 345-6057